Why Semaglutide + B12 Compounds Are No Longer Allowed
Key Takeaways
- Semaglutide + vitamin B12 combinations were marketed as a "different product" to justify compounding — the FDA disagrees
- The FDA's position: adding B12 doesn't make semaglutide a new compound that avoids the original drug's regulatory status
- This affected primarily 503B outsourcing facilities that used the B12 addition as a legal workaround
- 503A pharmacies can still compound semaglutide with B12 if a provider specifically prescribes the combination for an individual patient
- The B12 component itself has minimal clinical significance at the doses typically used
For over a year, the most common compounded semaglutide product was "semaglutide with B12" or "semaglutide/cyanocobalamin." The B12 wasn't just a health bonus — it was a legal strategy. Here's what happened and why it matters.
The Legal Workaround
When semaglutide came off the shortage list, 503B facilities needed a new legal basis to continue compounding. Some argued that "semaglutide + B12" was a different product — a combination that didn't exist as an FDA-approved drug, and therefore could be compounded under different rules. The FDA rejected this reasoning, stating that adding a common vitamin to an existing drug doesn't create a genuinely new therapeutic product.
What This Means for Patients
If you've been using compounded "semaglutide with B12," the practical impact depends on your pharmacy type:
| Pharmacy Type | Impact | Patient Action |
|---|---|---|
| 503A (patient-specific Rx) | Minimal — can still compound with B12 if prescribed | Verify your Rx is patient-specific |
| 503B (outsourcing) | Significant — B12 workaround no longer viable | May need to switch to 503A provider |
At the doses typically included in compounded semaglutide (1,000–5,000 mcg), B12 has minimal clinical impact for most patients. B12 deficiency is uncommon in the general population, and GLP-1 medications don't significantly deplete B12. The B12 was primarily a legal/marketing tool, not a meaningful therapeutic addition.
Embody
GLP-1 · LeadCompounded injectable semaglutide. Established program, strong clinical support. Lead anchor provider.
Gala
GLP-1Compounded injectable semaglutide at $179/month flat pricing. Injection-only.
The B12 workaround is dead as a legal strategy for 503B facilities. 503A pharmacies can still compound semaglutide with B12 if a provider prescribes the specific combination. For patients, the important thing isn't whether your product contains B12 — it's whether your pharmacy operates under a legitimate 503A patient-specific model.
GLP-1 Compound Pharmacy Editorial
Independent compounding pharmacy research. 503A/503B analysis, safety verification, regulatory tracking. Not medical advice.